Paul Matteis
Stock Analyst at Stifel
(1.27)
# 4,683
Out of 4,792 analysts
111
Total ratings
34.72%
Success rate
-13.52%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $262.16 | +31.60% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $0.85 | +135.57% | 2 | Mar 7, 2025 | |
| RYTM Rhythm Pharmaceuticals | Reinstates: Buy | $78 | $49.82 | +56.56% | 1 | Mar 5, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $11.61 | +175.62% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $9.86 | +224.54% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $2.83 | +288.69% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $484.01 | +2.06% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $9.75 | +228.21% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $7.37 | -18.59% | 5 | Dec 16, 2024 | |
| ALEC Alector | Downgrades: Hold | $4 | $1.09 | +266.97% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $1.85 | +440.54% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $9.67 | +520.48% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $31.66 | +13.71% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $67.48 | +28.93% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $66 | $9.42 | +600.64% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $8.52 | +310.80% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $28.52 | +85.83% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $16.12 | +30.27% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $6.13 | +373.08% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $102.88 | +39.97% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $130.71 | +119.57% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.64 | +657.58% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $2.28 | +426.32% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.26 | +1,812.35% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.26 | +1,823.08% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $11.32 | +182.69% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.67 | +1,337.13% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $0.99 | +2,632.79% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $7.20 | +94.44% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.64 | +863.86% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $17.82 | +1,807.97% | 1 | Dec 21, 2016 |
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $262.16
Upside: +31.60%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $0.85
Upside: +135.57%
Rhythm Pharmaceuticals
Mar 5, 2025
Reinstates: Buy
Price Target: $78
Current: $49.82
Upside: +56.56%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $11.61
Upside: +175.62%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $9.86
Upside: +224.54%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $2.83
Upside: +288.69%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $484.01
Upside: +2.06%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $9.75
Upside: +228.21%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $7.37
Upside: -18.59%
Alector
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.09
Upside: +266.97%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $1.85
Upside: +440.54%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $9.67
Upside: +520.48%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $31.66
Upside: +13.71%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $67.48
Upside: +28.93%
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $9.42
Upside: +600.64%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $8.52
Upside: +310.80%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $28.52
Upside: +85.83%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $16.12
Upside: +30.27%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $6.13
Upside: +373.08%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $102.88
Upside: +39.97%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $130.71
Upside: +119.57%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $2.64
Upside: +657.58%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $2.28
Upside: +426.32%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.26
Upside: +1,812.35%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.26
Upside: +1,823.08%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.32
Upside: +182.69%
Feb 1, 2022
Initiates: Buy
Price Target: $24
Current: $1.67
Upside: +1,337.13%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $0.99
Upside: +2,632.79%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $7.20
Upside: +94.44%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.64
Upside: +863.86%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $17.82
Upside: +1,807.97%